Data from a retrospective study presented at the American College of Gastroenterology 2024 Annual Scientific Meeting suggests that the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may decrease the risk of early-onset colorectal cancer (EO-CRC) in patients with type 2 diabetes (T2D). The study analyzed patients under 50 years old with T2D who were prescribed antidiabetic medications, with a focus on first-time GLP-1 RA users. Results showed that patients taking GLP-1 RAs had significantly lower odds of developing EO-CRC. The study suggests a potentially protective role of GLP-1 RAs in combating the rising incidence of EO-CRC in younger adults.
Source link
GLP-1 RAs Reduce Early-Onset Colorectal Cancer Risk in T2D
